India Launches World's First Clinical Trial Integrating Ayurveda with Tuberculosis Treatment
Key Insights
India has announced the world's first clinical study to scientifically evaluate Ayurveda (search) as an adjunct to standard Anti-Tuberculosis Treatment (search), marking a historic convergence of traditional medicine and modern biotechnology.
The landmark study will enroll 1,250 newly diagnosed TB (search) patients across eight premier institutions, focusing on nutritional recovery, disease progression, quality of life improvements, and safety of integrative therapy.
India accounts for approximately 25% of the global TB (search) burden but has achieved a 21% decline in incidence since 2015, with TB cases reduced to 187 per 100,000 population in 2024.
India has launched the world's first clinical trial to scientifically evaluate Ayurveda (search) as an adjunct to standard tuberculosis (search) treatment, marking a groundbreaking convergence of traditional medicine and modern biotechnology. Announced on World Tuberculosis Day by Union Minister Dr. Jitendra Singh, the initiative represents what he described as a "whole-of-science and whole-of-government approach" to deliver holistic, patient-centric TB (search) care.
Landmark Study Design and Scope
The collaborative study between the Department of Biotechnology (search) (DBT) and the Ministry of Ayush will enroll 1,250 newly diagnosed TB (search) patients across eight premier institutions in India. This first-of-its-kind global study will evaluate Ayurveda (search) as a supportive therapy alongside standard TB drugs, focusing on several key areas:
- Nutritional recovery and weight gain
- Disease progression and treatment outcomes
- Quality of life improvements
- Safety and tolerability of integrative therapy
According to Prof. Vaidya Rabinarayan Acharya, Director General of the Central Council for Research in Ayurvedic Sciences (CCRAS (search)), the initiative has been developed under a memorandum of understanding signed between the Ministry of Ayush and the Department of Biotechnology (search) on May 25, 2022.
India's TB Burden and Progress
India, which accounts for approximately 25% of the global TB (search) burden, has made notable progress in reducing disease incidence. TB cases have declined to 187 per 100,000 population in 2024, reflecting a 21% reduction since 2015. This progress is attributed to strengthened efforts under the National TB Elimination Programme, including early diagnosis, universal drug susceptibility testing, digital adherence technologies, and patient-centric treatment approaches.
However, significant challenges persist, including drug-resistant TB (search), treatment-related toxicity, undernutrition and immune suppression, and long-term lung damage even after cure. Dr. Jitendra Singh emphasized that "even after cure, many patients suffer from weakness, weight loss, and reduced quality of life."
Advanced Scientific Methodology
The trial will deploy cutting-edge scientific tools to evaluate outcomes comprehensively. Dr. Debasisa Mohanty, Director of BRIC-National Institute of Immunology (search), explained that the study will examine tuberculosis (search)-associated cachexia (search) as an immune-metabolic condition using advanced tools including:
- DEXA and MRI scans for body composition analysis
- Immune profiling and metabolomics
- Single-cell RNA sequencing
These technologies will help researchers understand changes in body composition, immune function, and energy metabolism, and assess how integrative interventions influence recovery and long-term outcomes.
Addressing Treatment Gaps
The study aims to explore how Ayurveda (search) can improve nutrition and immunity, support post-treatment recovery, and address host-directed therapy gaps. Dr. Jitendra Singh noted that tuberculosis (search) cannot be seen in isolation, pointing out the reciprocal relationship between TB (search) and conditions such as diabetes (search), where each can aggravate the other, making integrated approaches essential for effective disease management.
DBT's Expanding TB Research Portfolio
The Department of Biotechnology (search) has been at the forefront of TB (search) innovation through several key initiatives:
The RePORT India Programme, one of the largest TB (search) research consortia, has enrolled over 4,500 TB patients and more than 5,000 household contacts, generating evidence that has contributed to global policy frameworks, including WHO guidelines on nutrition and tuberculosis (search).
The Indian TB (search) Genomic Surveillance (InTGS) initiative has sequenced more than 32,000 Mycobacterium tuberculosis (search) clinical strains, creating a valuable national repository to support drug discovery, diagnostics, and containment of drug-resistant TB.
Collaborative Leadership
The programme brings together leading institutions and experts, with Union Minister Prataprao Jadhav of the Ministry of Ayush noting that the initiative reflects a broader vision of healthcare where the focus extends beyond curing infection to ensuring complete recovery, improved nutrition, and enhanced quality of life through integration of Ayurveda (search) with modern medicine.
DBT Secretary Dr. Rajesh S. Gokhale said the programme builds on the Department of Biotechnology (search)'s extensive work in TB (search) research and represents an important step towards generating evidence for integrative and patient-centric healthcare approaches.
Global Implications
Dr. Jitendra Singh concluded that the fight against tuberculosis (search) requires innovation, integration, and collective responsibility at every level, adding that such initiatives will accelerate India's journey towards a TB (search)-free nation while setting a global example in combining traditional wisdom with modern science. The Minister emphasized that TB elimination cannot rely solely on government efforts but requires community participation, awareness campaigns, and urgent action to remove stigma associated with the disease.